This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …

Smoking cessation has reduced the incidence of lung cancer. The authors of this review
discuss recent progress in diagnostic and treatment approaches, including molecular …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …

Purpose Provide evidence-based recommendations updating the 2015 ASCO guideline on
systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC). Methods …

Osteosarcoma is the most common primary malignant bone tumour in children and
adolescents. Due to micrometastatic spread, radical surgery alone rarely results in cure …

The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …

Introduction: Protein kinases are involved in various cellular functions. About 2% of the
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …

Members of the human epidermal growth factor receptor (HER) family, which includes HER1
(also known as EGFR), HER2, HER3 and HER4, have played a central role in regulating cell …

Lung squamous cell carcinoma (LUSC) represents a major subtype of lung cancer with
limited treatment options. KMT2D is one of the most frequently mutated genes in LUSC (> …